On 1 January 2026, Denmark's medical cannabis scheme stopped being a pilot. Bill L 135, adopted by the Danish Parliament on 24 April 2025, turned the 2018 trial into a permanent programme and kept the patient subsidy unchanged. For Canadian Licensed Producers, that removed the biggest objection to Denmark: the risk that the market would simply expire.
Exporting cannabis to Denmark from Canada works through a Danish partner, not a direct sale to pharmacies. Your partner needs an authorisation from the Danish Medicines Agency (DKMA) to manufacture cannabis intermediate products. Your flower must be admitted to the DKMA's programme list. Each shipment then needs a Danish import permit and a matching Health Canada export permit.
How Denmark's permanent medical cannabis programme works in 2026
Danish doctors can prescribe cannabis through four routes: authorised medicines, compassionate-use permits, magistral preparations made by pharmacies, and products admitted to the medical cannabis programme. Dried flower from a Canadian LP fits only the last route. Any Danish doctor can prescribe programme products, but none is obliged to.
The subsidy model carried over from the pilot. Most patients receive a 50% subsidy capped at DKK 10,000 a year, and terminally ill patients are fully reimbursed. That cap matters for your pricing, because the patient pays the balance out of pocket.
A small market with a concentrated flower shelf
Denmark is not Germany. Industry estimates put the total Danish medical cannabis market at roughly DKK 60 million a year over the last several years. As of April 2026, Business of Cannabis listed five flower products in the programme, all from Bedrocan in the Netherlands.
That's an opening. A single-supplier flower shelf means Danish pharmacies and prescribers have limited choice of cultivar or potency. A Canadian LP with consistent, well-documented flower is offering something the list currently lacks.
Denmark exports more than it imports
Danish producers shipped more than 7 tonnes of medical cannabis to Germany in 2024, according to Prohibition Partners. Domestic cultivators supply export markets, while Danish patients rely on imported flower. Inside Denmark, you compete with the import list.
The Canada-Denmark supply path: 5 steps
We call the route below the Canada-Denmark Supply Path. Each step depends on the one before it, so the order is not optional.
| Step | Who acts | Key output |
|---|---|---|
| 1. Secure a Danish partner | Danish importer | DKMA intermediate product authorisation |
| 2. Product admission | Danish partner, with your dossier | Listing on the DKMA programme list |
| 3. Price notification | Danish partner | Price filed via DKMAnet |
| 4. Permit chain | DKMA, then Health Canada | Danish import permit, Canadian export permit |
| 5. Batch release | Partner's competent person | Released batch for pharmacies |
Step 1: Secure a Danish partner with the right authorisation
A company that wants to import cannabis primary products into Denmark must hold a DKMA authorisation to manufacture cannabis intermediate products. It also needs an authorisation to handle euphoriant substances. Without both, your partner can't receive your flower. Ask for the authorisation and the site addresses it covers before you discuss price, because DKMA authorisations are site-specific.
Step 2: Get the product admitted to the DKMA list
Your partner applies to have the intermediate product and your primary product admitted to the DKMA's list of programme products. Section 5 of the Danish act sets the requirements for imported primary products, and the DKMA updated its application forms, product sheet template, and patient information sheet template on 4 June 2026. Most forms are in Danish only, so budget for translation. Applications go in through Eudralink or the Common European Submission Portal.
Step 3: File the price
Admission alone doesn't put your product in front of doctors. The package prices must be notified to DKMA Medicine Prices through DKMAnet. Only then does the product appear on medicinpriser.dk, where prescribers look.
Step 4: Run the permit chain
Denmark issues the import permit first. Health Canada then issues the export permit under the Cannabis Regulations, and it needs the Danish permit to do so. This is the same two-permit chain used for every medical market. The quantity must also fit within Denmark's estimates filed with the INCB, so check your volumes against INCB import quotas early.
Step 5: Batch release by the competent person
Every batch is released in Denmark by your partner's competent person, a role the DKMA compares to a GMP qualified person. This person must be independent of management and sales and present at the company regularly, not only on release days. The DKMA accepts quality agreements that split release duties between companies, applying the principles of EU-GMP Annex 16. In practice, that means a signed quality agreement and an audit of your facility.
What Danish importers check before they sign
The paperwork in Denmark is lighter than in Germany, but the quality bar is not. Four issues decide most Danish deals.
GMP evidence
Danish cannabis manufacturers must follow the European Commission's EU-GMP guidelines. Your partner's competent person carries that standard into every release decision. A Canadian site with EU-GMP certification shortens the conversation. Without it, expect a detailed audit and a longer qualification timeline.
Pesticide inputs
The pilot programme banned pesticide use for imported primary products. L 135 changed that: pesticides can now be used in cultivation under rules set by executive order from 2026. The question has moved from "did you use anything?" to "did you use only what Denmark permits?" Send your integrated pest management records with your first dossier, and check every input against the current Danish list.
No re-export
Imported cannabis primary products cannot be exported from Denmark, either as primary or intermediate products. Denmark is a destination, not a hub. If your plan relies on routing Canadian flower through Denmark to Germany, it won't work. The new route for Danish companies to import cannabis for further processing is framed around EU-grown material, so it doesn't change this for Canadian supply.
No advertising
Danish law prohibits advertising for programme products. Doctors learn about your flower through the DKMA product sheet published once the product is admitted. That sheet is your only marketing page, so the data you put into it needs to be accurate and complete.
Common mistakes Canadian LPs make with Denmark
The first mistake is sizing Denmark like Germany. At roughly DKK 60 million a year, the whole market is small next to Germany's medical flower channel. Denmark makes sense as a second or third EU market for an LP that already has its GMP and permit systems running, not as a first export.
The second is pricing without the subsidy cap in mind. Patients cover half the cost up to DKK 10,000 a year and everything above it. A premium price that works in a fully reimbursed channel can stall at Danish pharmacy counters.
The third is treating the Danish partner as a distributor. Your partner is a licensed manufacturer that takes legal responsibility for release. Choose one with an approved competent person, a track record of admitted products, and the capacity to handle Danish-language filings.
Our view: Denmark is worth entering now, while the flower list is thin. Once a second or third supplier is admitted, the advantage of being early is gone.
AlphaLeaf is a Montreal-based Health Canada Licensed Producer of indoor-grown, hand-trimmed cannabis flower with refined genetics. We hold export authorisation under the Cannabis Act and keep the ISO/IEC 17025-tested batch data and full traceability records that Nordic importers and their competent persons review before release.
If you're a Danish importer looking for a second source of medical-grade flower, contact AlphaLeaf to request our product documentation.
Frequently Asked Questions
Can a Canadian Licensed Producer export cannabis to Denmark?
Yes. A Canadian LP can supply Denmark's medical cannabis programme through a Danish partner authorised by the Danish Medicines Agency to manufacture cannabis intermediate products. The product must be admitted to the agency's programme list, and each shipment needs a Danish import permit and a Health Canada export permit.
Who issues cannabis import permits in Denmark?
The Danish Medicines Agency (DKMA) is the competent authority for medical cannabis in Denmark. It authorises importers, admits products to the programme list, and handles the permits for euphoriant substances, including cannabis.
Does imported cannabis flower need GMP to enter Denmark?
Yes, in practice. Danish cannabis manufacturers must follow EU-GMP guidelines, and the Danish partner's competent person releases each batch against that standard. A Canadian site with EU-GMP certification or a successful partner audit is far easier to qualify.
Can cannabis imported into Denmark be re-exported to Germany?
No. Imported cannabis primary products cannot be exported from Denmark, either as primary products or as intermediate products. Only Danish-grown cannabis primary products and cannabis bulk can be exported under Danish rules.
Is medical cannabis reimbursed in Denmark?
Yes. Programme products carry a 50% subsidy capped at DKK 10,000 a year for most patients, and terminally ill patients are fully reimbursed. Bill L 135 kept this subsidy unchanged when the programme became permanent on 1 January 2026.
Are pesticides allowed on cannabis supplied to Denmark?
The pilot programme banned them for imported products. Bill L 135 allows pesticide use in cultivation under rules set by executive order from 2026, so Canadian LPs should check each input in their pest management records against the current Danish list.
